DYN Q1 2016 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q1 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$168M-73.4% YoY

Gross Profit

-$377M-224.4% margin

Operating Income

$145M86.3% margin

Net Income

-$10M-6.0% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

-22.6%

Cash Flow

Operating Cash Flow

$191M

Free Cash Flow

$126M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$11.7B

Total Liabilities

$8.8B

Stockholders' Equity

$2.9B

Cash & Equivalents

$821M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$168M	$632M	-73.4%
Gross Profit	-$377M	$255M	-247.8%
Operating Income	$145M	-$1M	+14600.0%
Net Income	-$10M	-$180M	+94.4%